Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Blue Earth Diagnostics to Present New Molecular Imaging Data Advancing Patient Outcomes at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting


      News provided by

      Blue Earth Diagnostics

      May 19, 2026, 07:00 ET

      Share this article

      Share this article


      Bracco | Blue Earth Diagnostics Logo
      Bracco | Blue Earth Diagnostics Logo

      BOSTON, May 19, 2026 /PRNewswire/ -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that nine abstracts featuring the latest data on its growing portfolio and pipeline will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, held from May 30–June 2, in Los Angeles, CA. The presentations will showcase expanding clinical and preclinical evidence supporting novel PET imaging agents designed to improve prostate cancer detection, including findings from an intra-patient, head-to-head comparator study of POSLUMA® (flotufolastat F 18) and piflufolastat F 18.

      Across multiple studies, POSLUMA® demonstrated strong performance in detecting biochemical recurrence following radical prostatectomy, particularly at low prostate-specific antigen (PSA) levels where conventional imaging remains limited. Additional data from a prospective clinical study underscores the potential utility of Axumin® (fluciclovine F 18) in patients with negative or inconclusive prostate-specific membrane antigen (PSMA) PET scans, supporting continued innovation in prostate cancer imaging.

      "PET radiopharmaceuticals can transform uncertainty into precision by providing clinicians with early insights to identify clinically meaningful answers when decisions cannot wait," said Marco Campione, President and CEO of Blue Earth Diagnostics. "The data presented at SNMMI showcase our commitment to advancing nuclear medicine and enhancing patient outcomes through cutting-edge molecular imaging solutions, which facilitate precise, timely, and confident clinical decision-making."

      Blue Earth Diagnostics invites attendees of the 2026 SNMMI Annual Meeting to participate in the Satellite Symposium titled, "Precision in PSMA: Why Agent Selection Matters More Than Ever" on Sunday, May 31, from 11:15 AM to 12:15 PM PT in Petree Hall C. Additionally, please visit the Bracco | Blue Earth Diagnostics Exhibit Booth #1823. For complete details on the sessions and a list of scientific presentations, please check the SNMMI online program.

      POSLUMA (flotufolastat F 18)
      DATE: Sunday, May 31, 2026
      Title: Intra-patient Contemporaneous Comparator Study of the Qualitative Assessment of Urinary Radioactivity of 18F-Piflufolastat and 18F Flotufolastat PET/CT in Patients with Low PSA Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy 
      Presenter: Phillip H. Kuo, MD, Kuo Radiology LLC
      Session Type: Poster presentation
      Session Time: 5:30 – 6:15 PM CT
      Abstract ID.: 261637

      DATE: Sunday, May 31, 2026
      Title: Intra-patient Contemporaneous Comparator Study of Normal-Organ Distribution of PSMA-Targeting PET Radiopharmaceuticals, 18F-Piflufolastat and 18F-Flotufolastat, in Patients with Low PSA Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy
      Presenter: Phillip H. Kuo, MD, Kuo Radiology LLC
      Session Type: Poster presentation
      Session Time: 5:30 – 6:15 PM CT
      Abstract ID.: 261643

      DATE: Sunday, May 31, 2026
      Title: Positive Predictive Value of 18F-Flotufolastat PET in Patients with Biochemical Recurrence of Prostate Cancer: Radio-Guided Salvage Surgery and Histological Validation
      Presenter: Daniel Sasse, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine München, Germany
      Session Type: Poster presentation
      Session Time: 5:30 – 6:15 PM CT
      Abstract ID.: 202066

      DATE: Sunday, May 31, 2026
      Title: Intraindividual Comparison of Unspecific Bone Uptake Between 18F-Flotufolastat and 18F-PSMA-1007 PET/CT in Patients with Prostate Cancer
      Presenter: Daniel Sasse, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine München, Germany
      Session Type: Poster presentation
      Session Time: 5:30 – 6:15 PM CT
      Abstract ID.: 261004

      DATE: Sunday, May 31, 2026
      Title: Real-world Detection Efficacy of ¹⁸F-Flotufolastat PET/CT
      Presenter: Daniel Sasse, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine München, Germany
      Session Type: Poster presentation
      Session Time: 5:30 – 6:15 PM CT
      Abstract ID.: 262312

      DATE: Sunday, May 31, 2026
      Title: Tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer (mHSPC): Initial Results from PSMATrack
      Presenter: Heather Jacene, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
      Session Type: Poster presentation 
      Session Time: 5:30 – 6:15 PM CT 
      Abstract ID.: 262165 

      Axumin (fluciclovine F 18)
      DATE: Sunday, May 31, 2026
      Title: The REFINE Study – A Prospective Clinical Trial: Uncovering Prostate Cancer Biochemical Recurrence with 18F-Fluciclovine After Negative PSMA PET
      Presenter: Theo Lorenzini, Technical University of Munich, School of Medicine, TUM Klinikum rechts der Isar, Department of Nuclear Medicine Munich, Germany
      Session Type: Oral presentation
      Session Time: 1:20 – 1:30 PM PT
      Abstract ID.: 262074

      DATE: Tuesday, June 2, 2026
      Title: Imaging Heterogeneity in Neuroendocrine Prostate Cancer on Paired PSMA and F18-Fluciclovine PET/CT
      Presenter: Heather Jacene, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
      Session Type: Poster presentation
      Session Time: 11:30 – 12:15 pm PT 
      Abstract ID.: 261277 

      64Cu-rhPSMA-7.3/Pipeline
      DATE: Tuesday, June 2, 2026
      Title: 64Cu-rhPSMA-7.3 for Imaging Prostate Cancer: A Preclinical Proof of Concept Study
      Presenter: George Pope
      Session Type: Poster presentation
      Session Time: 11:30 – 12:15 PM CT
      Abstract ID.: 261612

      About Bracco

      Bracco group, founded in 1927, is a global leader in diagnostic imaging, committed to advancing healthcare and improving people's lives by shaping the future of prevention and precision medicine.

      The company operates in the healthcare sector across more than 100 countries with a workforce of over 4,000 employees and consolidated annual revenues of approximately €2 billion, 88% generated by international markets.

      With a strong commitment to innovation - investing around 9% of its reference turnover in Research & Development -  Bracco develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well as microbubbles for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers and novel PET imaging agents, alongside AI-based solutions. It is also a global market leader in advanced contrast management technologies for cardiovascular angiography and radiology imaging.

      Discover more at www.bracco.com

      About Blue Earth Diagnostics

      Blue Earth Diagnostics, a subsidiary of Bracco Imaging, is a global company advancing precision molecular imaging to support timely decisions and better patient outcomes. Founded in 2014, we work closely with clinicians and collaborators, bringing deep expertise to the development and delivery of positron emission tomography (PET) radiopharmaceuticals. Our growing portfolio helps uncover disease sooner and guide treatment choices across multiple disease states, including oncology and cardiology. Backed by a dedicated team, we deliver clear answers when decisions matter most.

      For more information, please visit: www.blueearthdiagnostics.com.

      POSLUMA® is a registered trademark of Blue Earth Diagnostics

      U.S. Indication and Important Safety Information About POSLUMA

      INDICATION

      POSLUMA® (flotufolastat F 18) injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer

      • with suspected metastasis who are candidates for initial definitive therapy
      • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level

      IMPORTANT SAFETY INFORMATION

      • Image interpretation errors can occur with POSLUMA PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of POSLUMA for imaging metastatic pelvic lymph nodes in patients prior to initial definitive therapy seems to be affected by serum PSA levels and risk grouping. The performance of POSLUMA for imaging patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. Flotufolastat F 18 uptake is not specific for prostate cancer and may occur in other types of cancer, in non-malignant processes, and in normal tissues. Clinical correlation, which may include histopathological evaluation, is recommended.

      • Risk of Image Misinterpretation in Patients with Suspected Prostate Cancer Recurrence: The interpretation of POSLUMA PET may differ depending on imaging readers, particularly in the prostate/prostate bed region. Because of the associated risk of false positive interpretation, consider multidisciplinary consultation and histopathological confirmation when clinical decision-making hinges on flotufolastat F 18 uptake only in the prostate/prostate bed region or only on uptake interpreted as borderline.

      • POSLUMA use contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Advise patients to hydrate before and after administration and to void frequently after administration. Ensure safe handling to minimize radiation exposure to the patient and health care providers.

      • The adverse reactions reported in ≥0.4% of patients in clinical studies were diarrhea, blood pressure increase and injection site pain.

      • Drug Interactions: androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of flotufolastat F 18 in prostate cancer. The effect of these therapies on performance of POSLUMA PET has not been established.

      To report suspected adverse reactions to POSLUMA, call 1-844-POSLUMA (1-844-767-5862) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

      Full POSLUMA prescribing information is available at www.posluma.com/prescribing-information.pdf.

      U.S. Indication and Important Safety Information About Axumin

      INDICATION

      Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

      IMPORTANT SAFETY INFORMATION

      • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.

      • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.

      • Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.

      • Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

      To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

      Please see Axumin full Prescribing Information.

      Contact: 
      For Blue Earth Diagnostics
      Monica Planinsek
      Corporate Communications Manager
      [email protected]
      (M) (207) 838-3863

      Media 
      Shannon Moore
      [email protected]
      (M) (714) 348-483

      SOURCE Blue Earth Diagnostics

      Modal title

      Also from this source

      Blue Earth Diagnostics to Present New Research Advancing Precision Molecular Imaging at ASTRO 2026

      Blue Earth Diagnostics to Present New Research Advancing Precision Molecular Imaging at ASTRO 2026

      Blue Earth Diagnostics, part of the Bracco Group and recognized leader in the development and commercialization of innovative positron emission...

      Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in Men with Biochemical Recurrence of Prostate Cancer

      Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in Men with Biochemical Recurrence of Prostate Cancer

      Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Medical Equipment

      Medical Equipment

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.